CLINICAL TRIALS PROFILE FOR ERYTHROMYCIN

All Clinical Trials for ERYTHROMYCIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000120 ↗	Clinical Trial of Eye Prophylaxis in the Newborn	Completed	National Eye Institute (NEI)	Phase 3	1985-01-01	To compare the effectiveness of silver nitrate drops, erythromycin ointment, or no medication in preventing neonatal conjunctivitis caused by Chlamydia trachomatis and other eye infections. To compare side effects of the two prophylactic agents.
NCT00002194 ↗	An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.	Completed	Boehringer Ingelheim	Phase 1	1969-12-31	To evaluate the potential pharmacokinetic interaction between nevirapine and clarithromycin, and to determine the effects of nevirapine on cytochrome P450 3A4 (CYP3A4) activity in vivo.
NCT00004564 ↗	The Inhibition of Platelet Antiaggregating Activity of Clopidogrel by Atorvastatin Detected by Erythromycin Breath Test: a Metabolic Inhibition of Hepatic Cytochrome P450-3A	Unknown status	National Center for Research Resources (NCRR)	N/A	1969-12-31	The objective of this study is to determine if the action of the drug called clopidogrel, that you will start taking, will be decreased by another drug called atorvastatin, that you will also start taking. Clopidogrel is an oral antiplatelet agent that has been shown to prevent strokes and heart attacks. Atorvastatin is a cholesterol lowering agent. Twenty adults 18-75 years of age requiring cholesterol-lowering agent and antiplatelet agent therapy will be recruited for this study during their cardiology clinic visitation. In one group, antiplatelet agent (clopidogrel) regimen will be administered first, then followed by cholesterol-lowering medication (atorvastatin). In the second group, atorvastatin will be administered first, followed by clopidogrel. A new test called the erythromycin breath test will be administered to you three times during the study to measure how your liver will metabolize these drugs. Blood samples will also be obtained to assess platelet function. The criteria for exclusion are patient refusal or inability to give written consent, patients with allergic reaction to erythromycin, patients with known bleeding problems, liver disease, significant lung disease kidney disease and pregnancy. Patients with psychiatric impairment and documented history of substance abuse will also be excluded from the study.
NCT00021671 ↗	Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission	Completed	National Institute of Mental Health (NIMH)	Phase 3	1969-12-31	The purpose of this study is to see if antibiotic drugs given to treat an infection of the uterus during pregnancy can reduce the chances of HIV being passed from an HIV-positive mother to her baby. A link between bacterial disease of the vagina, premature birth, infection of the uterus during pregnancy, and the passing of HIV from a mother to her baby has been found. Early treatment of these problems may reduce the risk of passing HIV from an HIV-positive mother to her baby. [Note: As of 02/21/03, enrollment into this study was halted because preliminary data showed that the study antibiotics were not effective in preventing mother-to-child HIV transmission.]
NCT00021671 ↗	Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission	Completed	National Institute on Drug Abuse (NIDA)	Phase 3	1969-12-31	The purpose of this study is to see if antibiotic drugs given to treat an infection of the uterus during pregnancy can reduce the chances of HIV being passed from an HIV-positive mother to her baby. A link between bacterial disease of the vagina, premature birth, infection of the uterus during pregnancy, and the passing of HIV from a mother to her baby has been found. Early treatment of these problems may reduce the risk of passing HIV from an HIV-positive mother to her baby. [Note: As of 02/21/03, enrollment into this study was halted because preliminary data showed that the study antibiotics were not effective in preventing mother-to-child HIV transmission.]

Clinical Trial Conditions for ERYTHROMYCIN

Condition Name

Condition Name for ERYTHROMYCIN
Intervention	Trials
Healthy	8
Cholera	4
Gastroparesis	3
Upper Gastrointestinal Bleeding	3

Condition MeSH

Condition MeSH for ERYTHROMYCIN
Intervention	Trials
Colorectal Neoplasms	6
Rupture	6
Pneumonia	6
Fetal Membranes, Premature Rupture	6

Clinical Trial Locations for ERYTHROMYCIN

Trials by Country

+

−

Trials by Country for ERYTHROMYCIN
Location	Trials
United States	76
Brazil	15
China	12
Spain	8
Belgium	6

Trials by US State

+

−

Trials by US State for ERYTHROMYCIN
Location	Trials
Tennessee	5
Kentucky	5
North Carolina	5
Florida	5
Minnesota	4

Clinical Trial Progress for ERYTHROMYCIN

Clinical Trial Phase

Clinical Trial Phase for ERYTHROMYCIN
Clinical Trial Phase	Trials
Phase 4	27
Phase 3	19
Phase 2/Phase 3	6

Clinical Trial Status

Clinical Trial Status for ERYTHROMYCIN
Clinical Trial Phase	Trials
Completed	79
Unknown status	19
Terminated	13

Clinical Trial Sponsors for ERYTHROMYCIN

Sponsor Name

Sponsor Name for ERYTHROMYCIN
Sponsor	Trials
International Centre for Diarrhoeal Disease Research, Bangladesh	5
Pfizer	4
Mahidol University	4

Sponsor Type

Sponsor Type for ERYTHROMYCIN
Sponsor	Trials
Other	168
Industry	52
NIH	9

Erythromycin: Clinical Trials, Market Analysis, and Projections

Introduction

Erythromycin, a macrolide antibiotic, has been a cornerstone in the treatment of various bacterial infections for decades. This article provides an update on the current clinical trials, market analysis, and future projections for erythromycin.

Clinical Trials Update

Current and Upcoming Trials

While erythromycin is an established antibiotic, there are ongoing and planned clinical trials that aim to explore its efficacy in different contexts and combinations. For instance, there is a focus on combination therapies that could enhance its therapeutic applications. However, specific trials directly involving erythromycin are not as prevalent as those for newer antibiotics or combination treatments.

One notable area of research involves the comparison of erythromycin with other macrolides, such as clarithromycin and azithromycin. A systematic review and meta-analysis published in the Journal of Infection and Chemotherapy highlighted that erythromycin is less effective than clarithromycin for treating community-acquired pneumonia (CAP)[4].

Limitations and Future Directions

The current clinical evidence suggests that erythromycin should be considered during shortages of other macrolides or when it is more affordable for the patient. However, its lower efficacy and higher rate of adverse reactions, particularly gastrointestinal issues, limit its use as a first-line treatment for CAP[4].

Future clinical trials may focus on optimizing erythromycin's use in specific patient populations or exploring new formulations that could mitigate its side effects and improve its efficacy.

Market Analysis

Market Size and Growth

The global erythromycin market is projected to experience significant growth. As of 2023, the market was valued at USD 15.3 billion and is expected to reach USD 26.0 billion by 2033, growing at a CAGR of 5.6% during the forecast period from 2024 to 2033[3].

Product Type and Application

Erythromycin tablets are the leading product type, accounting for 47.3% of the market, due to their effectiveness in treating various bacterial infections. Respiratory tract infections are the primary application, driving 38.9% of the demand. Hospital pharmacies dominate the distribution channels, with 53.7% of the market share, and hospitals are the major end-users, accounting for 61.2% of the market[3].

Regional Market

North America leads the erythromycin market with a 35% share, driven by high healthcare spending and advanced medical infrastructure. Emerging markets, such as India, also present significant growth opportunities due to improving healthcare access and a growing pharmaceutical market[3].

Market Drivers and Challenges

Drivers

• Prevalence of Bacterial Infections: The increasing incidence of bacterial infections globally drives the demand for effective antibiotics like erythromycin.
• Expanding Applications in Veterinary Medicine: Erythromycin's use in treating infections in livestock and companion animals is a significant driver of market growth[3].
• Research and Development: Ongoing R&D in new formulations and combination therapies is expected to expand erythromycin's market beyond its traditional antibiotic role[3].

Challenges

• Antibiotic Resistance: The rise in antibiotic resistance is a major challenge, reducing the efficacy of erythromycin and other antibiotics.
• Regulatory Approvals: Stringent regulatory approvals can hinder the introduction of new formulations and combination therapies.
• Side Effects: Erythromycin's association with gastrointestinal adverse reactions and treatment discontinuation rates can limit its use[4].

Market Projections

Emerging Markets

Expansion into emerging markets offers substantial growth opportunities. Companies that navigate the regulatory landscape and establish strong distribution networks in these regions can capture significant market share. Erythromycin can serve as a cost-effective alternative to newer, more expensive antibiotics in these markets[3].

Combination Therapies

The development of combination therapies, such as combining erythromycin with prokinetic agents for gastrointestinal motility disorders, presents a promising growth opportunity. These innovative treatments can expand erythromycin's market and position it as a versatile treatment option[3].

Veterinary Sector

The growing demand for effective veterinary antibiotics, driven by the increasing global consumption of meat and the expanding pet care market, will continue to support the market expansion of erythromycin in the veterinary sector[3].

Key Takeaways

• Market Growth: The erythromycin market is expected to grow from USD 15.3 billion in 2023 to USD 26.0 billion by 2033, with a CAGR of 5.6%.
• Product Dominance: Erythromycin tablets lead the market, and respiratory tract infections are the primary application.
• Regional Leadership: North America dominates the market, but emerging markets offer significant growth opportunities.
• Challenges and Opportunities: Despite challenges like antibiotic resistance and side effects, the market benefits from expanding applications in veterinary medicine and the development of combination therapies.

FAQs

What is the current market size of the erythromycin market?

The global erythromycin market was valued at USD 15.3 billion in 2023[3].

What is the projected growth rate of the erythromycin market?

The market is expected to grow at a CAGR of 5.6% from 2024 to 2033[3].

Which region leads the erythromycin market?

North America leads the erythromycin market with a 35% share[3].

What are the primary applications of erythromycin?

Respiratory tract infections account for 38.9% of the demand, making them the primary application[3].

What challenges does erythromycin face in the market?

Erythromycin faces challenges such as antibiotic resistance, stringent regulatory approvals, and higher rates of adverse reactions compared to other macrolides[3][4].

Sources

1. GSK Pipeline Assets and Clinical Trials Report Q3 2024 - GSK
2. Erythromycin Market is Booming Worldwide - OpenPR
3. Erythromycin Market Size, Share, Growth - MarketResearch.biz
4. Efficacy of Erythromycin vs Clarithromycin for Community-Acquired Pneumonia - Infectious Disease Advisor
5. Global Erythromycin Market Insights, Forecast to 2030 - QYResearch